Accelerate Diagnostics Inc

Most Recent

  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///AXDX RD Expenses
    Company & Industry Overviews

    What Are Accelerate Diagnostics’ Key Strengths?

    In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

    By Kenneth Smith
  • uploads///AXDX revenue growth
    Company & Industry Overviews

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

    By Kenneth Smith
  • uploads///How it works
    Company & Industry Overviews

    What’s the Competitive Landscape for Accelerate Diagnostics?

    Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

    By Kenneth Smith
  • uploads///AXDX market potential
    Company & Industry Overviews

    What’s the Potential Market for Accelerate Diagnostics’ Products?

    Accelerate Diagnostics’ (AXDX) pheno system utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.